Cargando…

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies

Hematologic malignancies are a large and heterogeneous group of neoplasms characterized by complex pathogenetic mechanisms. The abnormal regulation of epigenetic mechanisms and specifically, histone modifications, has been demonstrated to play a central role in hematological cancer pathogenesis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markouli, Mariam, Strepkos, Dimitrios, Piperi, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654260/ https://www.ncbi.nlm.nih.gov/pubmed/36362442 http://dx.doi.org/10.3390/ijms232113657

Ejemplares similares

Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis
por: Markouli, Mariam, et al.
Publicado: (2021)

Structure, Activity and Function of the SETDB1 Protein Methyltransferase
por: Markouli, Mariam, et al.
Publicado: (2021)

Epigenetic mechanisms regulate sex-specific bias in disease manifestations
por: Chlamydas, Sarantis, et al.
Publicado: (2022)

Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity
por: Markouli, Mariam, et al.
Publicado: (2021)

Advances on Epigenetic Drugs for Pediatric Brain Tumors
por: Skouras, Panagiotis, et al.
Publicado: (2023)

Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis
por: Markouli, Mariam, et al.
Publicado: (2022)

Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review
por: Anagnostakis, Filippos, et al.
Publicado: (2023)

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options
por: Manou, Maria, et al.
Publicado: (2023)

Bacillus Cereus in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

Histone Modifications and Their Targeting in Lymphoid Malignancies
por: Fernández-Serrano, Miranda, et al.
Publicado: (2021)

Advances on Liquid Biopsy Analysis for Glioma Diagnosis
por: Skouras, Panagiotis, et al.
Publicado: (2023)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Histone Variants and Their Chaperones in Hematological Malignancies
por: Kirkiz, Ecem, et al.
Publicado: (2023)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies
por: Yang, Jia, et al.
Publicado: (2020)

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
por: Bajbouj, Khuloud, et al.
Publicado: (2021)

Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010)

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies
por: Sauter, Camille, et al.
Publicado: (2022)

Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
por: Sorrentino, Claudia, et al.
Publicado: (2019)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities
por: Psilopatis, Iason, et al.
Publicado: (2023)

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
por: Federico, Mario, et al.
Publicado: (2011)

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
por: Imai, Yoichi, et al.
Publicado: (2016)

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
por: Liu, Ruiqi, et al.
Publicado: (2023)

Therapeutic Benefits of Selenium in Hematological Malignancies
por: Ehudin, Melanie A., et al.
Publicado: (2022)

Therapeutic Advances in Immunotherapies for Hematological Malignancies
por: Nogami, Ayako, et al.
Publicado: (2022)

Transcription Factors with Targeting Potential in Gliomas
por: Giannopoulou, Angeliki-Ioanna, et al.
Publicado: (2022)

Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies
por: Okabe-Kado, Junko, et al.
Publicado: (2012)

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014)

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
por: Khalili, Saeed, et al.
Publicado: (2023)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
por: Pal, Dilipkumar, et al.
Publicado: (2023)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies
por: Wang, Shifen, et al.
Publicado: (2023)

Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
por: Paudel, Yam Nath, et al.
Publicado: (2020)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Targeting DNA Repair Pathways in Hematological Malignancies
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i93k5lq28fmmjgp0qrjpv52mek